SIRT4 overexpression protects against diabetic nephropathy by inhibiting podocyte apoptosis

Shi,Jian‑Xia; Wang,Qi‑Jin; Li,Hui; Huang,Qin

doi:10.3892/etm.2016.3938

SIRT4 overexpression protects against diabetic nephropathy by inhibiting podocyte apoptosis

Authors:
- Jian‑Xia Shi
- Qi‑Jin Wang
- Hui Li
- Qin Huang
View Affiliations

Affiliations: Department of Endocrinology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, P.R. China
Published online on: November 30, 2016 https://doi.org/10.3892/etm.2016.3938
Pages: 342-348

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic nephropathy is a diabetic complication associated with capillary damage and increased mortality. Sirtuin 4 (SIRT4) plays an important role in mitochondrial function and the pathogenesis of metabolic diseases, including aging kidneys. The aim of the present study was to investigate the association between SIRT4 and diabetic nephropathy in a glucose-induced mouse podocyte model. A CCK‑8 assay showed that glucose simulation significantly inhibited podocyte proliferation in a time- and concentration‑dependent manner. Reverse transcription-quantitative polymerase chain reaction and western blot analysis showed that the mRNA and protein levels of SIRT4 were notably decreased in a concentration-dependent manner in glucose‑simulated podocytes. However, SIRT4 overexpression increased proliferation and suppressed apoptosis, which was accompanied by increases in mitochondrial membrane potential and reduced production of reactive oxygen species (ROS). Notably, SIRT4 overexpression downregulated the expression of apoptosis‑related proteins NOX1, Bax and phosphorylated p38 and upregulated the expression of Bcl‑2 in glucose‑simulated podocytes. In addition, SIRT4 overexpression significantly attenuated the inflammatory response, indicated by reductions in the levels of TNF-α, IL-1β and IL‑6. These results demonstrate for the first time that the overexpression of SIRT4 prevents glucose‑induced podocyte apoptosis and ROS production and suggest that podocyte apoptosis represents an early pathological mechanism leading to diabetic nephropathy.

View Figures

View References

1	Lopes AA: End-stage renal disease due to diabetes in racial/ethnic minorities and disadvantaged populations. Ethnic Dis. 19:(Suppl 1). S1-47–S1-51. 2009.
2	Kihm L: Hypertension and diabetic nephropathy. Exp Clin Endocrinol Diabetes. 124:333–334. 2016. View Article : Google Scholar : PubMed/NCBI
3	Glastras SJ, Tsang M, Teh R, Chen H, McGrath RT, Zaky AA, Pollock CA and Saad S: Maternal obesity promotes diabetic nephropathy in rodent offspring. Sci Rep. 6:277692016. View Article : Google Scholar : PubMed/NCBI
4	Kikkawa R, Koya D and Haneda M: Progression of diabetic nephropathy. Am J Kidney Dis. 41:(Suppl 1). S19–S21. 2003. View Article : Google Scholar : PubMed/NCBI
5	Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D'Agati V and Schmidt AM: Glucose, glycation and rage: Implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol. 14:1383–1395. 2003. View Article : Google Scholar : PubMed/NCBI
6	Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G and Cooper ME: The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 17:1762–1764. 2003.PubMed/NCBI
7	Kilpatrick ES, Rigby AS and Atkin SL: The diabetes control and complications trial: The gift that keeps giving. Nat Rev Endocrinol. 5:537–545. 2009. View Article : Google Scholar : PubMed/NCBI
8	Lewko B and Stepinski J: Hyperglycemia and mechanical stress: Targeting the renal podocyte. J Cell Physiol. 221:288–295. 2009. View Article : Google Scholar : PubMed/NCBI
9	Batlle D: Clinical and cellular markers of diabetic nephropathy. Kidney Int. 63:2319–2330. 2003. View Article : Google Scholar : PubMed/NCBI
10	Shah IM, Mackay SP and McKay GA: Therapeutic strategies in the treatment of diabetic nephropathy - a translational medicine approach. Curr Med Chem. 16:997–1016. 2009. View Article : Google Scholar : PubMed/NCBI
11	Brezniceanu ML, Liu F, Wei CC, Chénier I, Godin N, Zhang SL, Filep JG, Ingelfinger JR and Chan JS: Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes. 57:451–459. 2008. View Article : Google Scholar : PubMed/NCBI
12	Elmarakby AA and Sullivan JC: Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 30:49–59. 2012. View Article : Google Scholar : PubMed/NCBI
13	Guarente L: Calorie restriction and sirtuins revisited. Gene Dev. 27:2072–2085. 2013. View Article : Google Scholar : PubMed/NCBI
14	de Oliveira Saraiva A, Pontes LQ, Pinho LG, Bezerra MR Lobo, Braga H Alencar, Lima NN Rolim, de Vasconcelos CA Carvalho, Neto ML Rolim, de Lima Fihlo JL, dos Santos FA Brayner, et al: Ultrastructural aspects of cranial and peripheric nerves of cronically diabetic and malnourished rats: A short biochemical panorama. Int Arch Med. 8:2015.
15	Chalkiadaki A and Guarente L: Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol. 8:287–296. 2012. View Article : Google Scholar : PubMed/NCBI
16	Michishita E, Park JY, Burneskis JM, Barrett JC and Horikawa I: Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 16:4623–4635. 2005. View Article : Google Scholar : PubMed/NCBI
17	North BJ, Marshall BL, Borra MT, Denu JM and Verdin E: The human Sir2 ortholog, SIRT2, is an NAD⁺-dependent tubulin deacetylase. Mol Cell. 11:437–444. 2003. View Article : Google Scholar : PubMed/NCBI
18	Kume S, Uzu T, Horiike K, Chin-Kanasaki M, Isshiki K, Araki S, Sugimoto T, Haneda M, Kashiwagi A and Koya D: Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest. 120:1043–1055. 2010. View Article : Google Scholar : PubMed/NCBI
19	Shi JX, Wang QJ, Li H and Huang Q: Silencing of USP22 suppresses high glucose-induced apoptosis, ROS production and inflammation in podocytes. Mol Biosyst. 12:1445–1456. 2016. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Chatterjee S, Rhee YH and Ahn JC: Sulforaphene-carboplatin combination synergistically enhances apoptosis by disruption of mitochondrial membrane potential and cell cycle arrest in human non-small cell lung carcinoma. J Med Food. 19:860–869. 2016. View Article : Google Scholar : PubMed/NCBI
22	Zhao X, Ren X, Zhu R, Luo Z and Ren B: Zinc oxide nanoparticles induce oxidative DNA damage and ROS-triggered mitochondria-mediated apoptosis in zebrafish embryos. Aquat Toxicol. 180:56–70. 2016. View Article : Google Scholar : PubMed/NCBI
23	Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, Valenzuela DM, Yancopoulos GD, Karow M, Blander G, et al: SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell. 126:941–954. 2006. View Article : Google Scholar : PubMed/NCBI
24	Chen YR, Fang SR, Fu YC, Zhou XH, Xu MY and Xu WC: Calorie restriction on insulin resistance and expression of SIRT1 and SIRT4 in rats. Biochem Cell Biol. 88:715–722. 2010. View Article : Google Scholar : PubMed/NCBI
25	Mahlknecht U and Voelter-Mahlknecht S: Fluorescence in situ hybridization and chromosomal organization of the sirtuin 4 gene (Sirt4) in the mouse. Biochem Bioph Res Commun. 382:685–690. 2009. View Article : Google Scholar
26	Susztak K, Raff AC, Schiffer M and Böttinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 55:225–233. 2006. View Article : Google Scholar : PubMed/NCBI
27	Schiffer M, Mundel P, Shaw AS and Böttinger EP: A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem. 279:37004–37012. 2004. View Article : Google Scholar : PubMed/NCBI
28	Long J, Wang Y, Wang W, Chang BH and Danesh FR: MicroRNA-29c is a signature microRNA under high glucose conditions that targets sprouty homolog 1 and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem. 286:11837–11848. 2011. View Article : Google Scholar : PubMed/NCBI
29	Nilsson L, Burlaka I, Brismar H, Aperia A and Scott L: Glucose activation of the mitochondrial apoptotic pathway in proximal tubular cells and protective effect of ouabain signaling. FASEB J. 29:912–959. 2015.
30	Wang H, Madhusudhan T, He T, Hummel B, Schmidt S, Vinnikov IA, Shahzad K, Kashif M, Muller-Krebs S, Schwenger V, et al: Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: Protective effect of factor V Leiden in diabetic nephropathy. Blood. 117:5231–5242. 2011. View Article : Google Scholar : PubMed/NCBI
31	Bock F, Shahzad K, Wang H, Stoyanov S, Wolter J, Dong W, Pelicci PG, Kashif M, Ranjan S, Schmidt S, et al: Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Pro Nat Acad Sci USA. 110:648–653. 2013. View Article : Google Scholar
32	Ahmad A, Mondello S, Di Paola R, Mazzon E, Esposito E, Catania MA, Italiano D, Mondello P, Aloisi C and Cuzzocrea S: Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: A comparison with N-acetylcysteine. Eur J Pharmacol. 674:397–406. 2012. View Article : Google Scholar : PubMed/NCBI
33	Koshikawa M, Mukoyama M, Mori K, Suganami T, Sawai K, Yoshioka T, Nagae T, Yokoi H, Kawachi H, Shimizu F, et al: Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol. 16:2690–2701. 2005. View Article : Google Scholar : PubMed/NCBI
34	Galkina E and Ley K: Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol. 17:368–377. 2006. View Article : Google Scholar : PubMed/NCBI
35	Sun L and Kanwar YS: Relevance of TNF-α in the context of other inflammatory cytokines in the progression of diabetic nephropathy. Kidney Int. 88:662–665. 2015. View Article : Google Scholar : PubMed/NCBI
36	Elseweidy MM, Elswefy SE, Younis NN and Zaghloul MS: Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. Exp Biol Med (Maywood). 238:881–888. 2013. View Article : Google Scholar : PubMed/NCBI
37	Navarro JF, Milena FJ, Mora C, León C, Claverie F, Flores C and García J: Tumor necrosis factor-alpha gene expression in diabetic nephropathy: Relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int Suppl. 99:S98–S102. 2005. View Article : Google Scholar
38	Navarro JF, Mora C, Muros M and García J: Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant. 21:3428–3434. 2006. View Article : Google Scholar : PubMed/NCBI
39	Balasubramanyam M, Aravind S, Gokulakrishnan K, Prabu P, Sathishkumar C, Ranjani H and Mohan V: Impaired miR-146a expression links subclinical inflammation and insulin resistance in type 2 diabetes. Mol Cell Biochem. 351:197–205. 2011. View Article : Google Scholar : PubMed/NCBI
40	Wong CK, Ho AW, Tong PU, Yeung CY, Kong AP, Lun SW, Chan JC and Lam CW: Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol. 149:123–131. 2007. View Article : Google Scholar : PubMed/NCBI